http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ye-Seul Kim,이재우,Hee-Taik Kang,Yonghwan Kim,Hyo-Sun You 대한가정의학회 2020 Korean Journal of Family Medicine Vol.41 No.1
Background: Few studies have reported on the trends in influenza vaccination rates among cancer survivors in Korea. We investigated these trends over a recent 11-year period (2005–2015). Methods: Data were obtained from the Korea National Health and Nutrition Examination Survey (KNHANES) III– VI (2005–2015). After excluding individuals younger than 40 years of age, the participants included 2,210 cancer survivors (861 men and 1,349 women). We categorized these study participants into four groups according to age and sex. Results: The influenza vaccination rate decreased significantly among male cancer survivors, with rates of 74.8, 64.7, 56.2, and 55.2% (β coefficient=-0.257, P for trend <0.001) in KNHANES III, VI, V, and VI, respectively. While influenza vaccination rates decreased significantly among older male cancer survivors (≥65 years) (β coefficient=- 0.359, P for trend=0.017), they increased among older female cancer survivors (β coefficient=0.375, P for trend=0.011) from 2005 to 2015. Conclusion: Influenza vaccination rates in older cancer survivors significantly decreased in men but increased in women in successive KNHANES phases. Efforts are needed to improve immunization education and awareness, especially in older male cancer survivors.
Ustekinumab, an effective therapeutic option for erythrodermic psoriasis
( Ye Seul Kim ),( Ga Hee Jung ),( Je Min An ),( Kyu Uang Whang ),( Jong Suk Lee ),( Young Lip Park ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.1
Erythrodermic psoriasis is a severe form of psoriasis, presenting as prominent erythema, affecting the whole body. Ustekinumab (Stelara®) is a human monoclonal antibody targeting the p40 subunit shared by interleukin IL-12 and IL-23. Erythrodermic psoriasis has been an exclusion criteria in studies looking at the efficacy of ustekinumab against psoriasis, but recently, a few reports have proven its efficacy on erythrodermic psoriasis. Herein, we report 2 cases of erythrodermic psoriasis that successfully improved with ustekinumab. A 42-year-old man presented with a 7-year history of erythrodermic psoriasis and psoriatic arthritis. The patient was treated with ustekinumab 45 mg subcutaneously at 0, week 4, and every 12 weeks thereafter. At week 28, his Psoriasis Areaand Severity Index (PASI) score decreased from 64.8 to 9.6. The second case is a 26-year-old man suffering from erythrodermic psoriasis for 10 years. Four months after the first administration of ustekinumab, the patient achieved 75% improvement of the PASI score and 90% improvement after 112 weeks. Although further studies are required, it is likely that ustekinumab can be an effective therapeutic option for patients affected by erythrodermic psoriasis.
P288 : The effect of PPARa activator containing moisturizer in patients with facial erythema
( Ye Seul Kim ),( Han Eul Lee ),( Gang Mo Lee ),( Je Min An ),( Young Lip Park ),( Moon Kyun Cho ),( Jong Kyung Youm ),( Sang Hoon Lee ) 대한피부과학회 2013 대한피부과학회 학술발표대회집 Vol.65 No.2
Background: Atopic dermatitis, seborrheic dermatitis, irritant or allergic contact dermatitis, rosacea, and acne are skin diseases that cause repeated facial erythema. Topical steroids are used to treat these dermatologic condition and long term use of topical steroids can cause complication such as skin atrophy, telangiectasia, and steroid induced acneiform eruption. PPARα is known to regulate keratinocyte differentiation and proliferation, and also participates in wound healing and skin inflammation. Objectives: This study is about the effect of PPARα activator containing moisturizers in patients with facial erythema by improving anti-inflammatory action and skin barrier function. Methods: 32 patients were included in this study and they were applied with PPARα activator containing moisturizers in one side of the face, and the other side with moisturizers not containing PPARα activator. They were applied twice a day two days a week and the study was double blinded, body-split study. The patients were checked of skin hydration, TEWL, and erythema the first day of hospital visit and 2 weeks after the study. Clinical photo analysis was done for checking erythema index and the result was assessed with doctor and patient survey. Results: Patients applied with PPARα activator containing moisturizer showed significant decrease of erythema measurement using mexameter, and decreased erythema index from photo analysis. No significant difference was noted in skin hydration and TEWL. Conclusion: We confirmed the effect and safety of PPARα activator containing moisturizers and anticipate it as a useful treatment for patients with facial erythema.